Search Results 111-120 of 14922 for infliximab

  1. Psoriasis - Diagnosis and treatment - Mayo Clinic

    It's less effective than adalimumab and infliximab. It might cause upset stomach, loss of appetite and fatigue. People taking methotrexate long-term need ...

  2. Etanercept (subcutaneous route) - Side effects & dosage - Mayo Clinic

    Baricitinib; Cholera Vaccine, Live; Cyclophosphamide; Dengue Tetravalent Vaccine, Live; Infliximab; Influenza Virus Vaccine, Live; Measles Virus Vaccine, Live ...

  3. Etanercept-szzs (subcutaneous route) - Side effects & dosage - Mayo Clinic

    Baricitinib; Cholera Vaccine, Live; Cyclophosphamide; Dengue Tetravalent Vaccine, Live; Infliximab; Influenza Virus Vaccine, Live; Measles Virus Vaccine, Live ...

  4. Publications - Michael C. Stephens, M.D. - Mayo Clinic

    Safety and steroid-sparing experience using infliximab for Crohn's disease at a pediatric inflammatory bowel disease center. Am J Gastroenterol. 2003 Jan ...

  5. Publications - Manreet Kaur, M.B.B.S., M.D. - Mayo Clinic

    Steroid-refractory ulcerative colitis—ciclosporin or infliximab? Nat Rev Gastroenterol Hepatol. 2013; 10(1):8-9. Wang C, Hanly EK, Wheeler LW, Kaur M ...

  6. Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year - Mayo Clinic

    Has not previously received an approved biologic for CD (i.e., infliximab, adalimumab, certolizumab pegol, ustekinumab, natalizumab, vedolizumab or approved ...

  7. Publications - Sandra M. Herrmann, M.D. - Mayo Clinic

    Barbir EB, Mohan A, Koirala P, Gutierrez LE, Giesen CD, Lieske JC, Herrmann SM. Biomarker-guided infliximab therapy for immune checkpoint inhibitor-induced ...

  8. Crohn's disease - Doctors and departments - Mayo Clinic

    Learn about symptoms and treatment for this debilitating, but treatable, digestive condition.

  9. A Study to Evaluate Utilizing MRI for Earlier Diagnosis of Rheumatoid Arthritis - Mayo Clinic

    ... infliximab, abatacept, tocilizumab, sarilumab, tofacitinib, rituximab, or anakinra. Contraindications to contrast-enhanced MRI ( renal insufficiency with ...

  10. A Study of Subcutaneous Abatacept to Treat Diffuse Cutaneous Systemic Sclerosis - Mayo Clinic

    Infliximab, certolizumab, golimumab, ABA or adalimumab within ≤ 8 weeks; Anakinra within ≤ 1 week. Pulmonary disease with FVC ≤ 50% of predicted, or DLCO ...